Literature DB >> 32639233

Concentration-dependent mortality of chloroquine in overdose.

James A Watson1,2, Joel Tarning1,2, Richard M Hoglund1,2, Frederic J Baud3,4, Bruno Megarbane5,6, Jean-Luc Clemessy3,6,7, Nicholas J White1,2.   

Abstract

Hydroxychloroquine and chloroquine are used extensively in malaria and rheumatological conditions, and now in COVID-19 prevention and treatment. Although generally safe they are potentially lethal in overdose. In-vitro data suggest that high concentrations and thus high doses are needed for COVID-19 infections, but as yet there is no convincing evidence of clinical efficacy. Bayesian regression models were fitted to survival outcomes and electrocardiograph QRS durations from 302 prospectively studied French patients who had taken intentional chloroquine overdoses, of whom 33 died (11%), and 16 healthy volunteers who took 620 mg base chloroquine single doses. Whole blood concentrations of 13.5 µmol/L (95% credible interval 10.1-17.7) were associated with 1% mortality. Prolongation of ventricular depolarization is concentration-dependent with a QRS duration >150 msec independently highly predictive of mortality in chloroquine self-poisoning. Pharmacokinetic modeling predicts that most high dose regimens trialled in COVID-19 are unlikely to cause serious cardiovascular toxicity.
© 2020, Watson et al.

Entities:  

Keywords:  bayesian; chloroquine; human; human biology; medicine; overdose; pharmacodynamics; pharmacokinetics

Mesh:

Substances:

Year:  2020        PMID: 32639233      PMCID: PMC7417172          DOI: 10.7554/eLife.58631

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  44 in total

1.  The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters.

Authors:  A Wozniacka; I Cygankiewicz; M Chudzik; A Sysa-Jedrzejowska; J K Wranicz
Journal:  Lupus       Date:  2006       Impact factor: 2.911

2.  [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].

Authors: 
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2020-03-12

3.  Treatment of severe chloroquine poisoning.

Authors:  B Riou; P Barriot; A Rimailho; F J Baud
Journal:  N Engl J Med       Date:  1988-01-07       Impact factor: 91.245

4.  Chloroquine poisoning in Zimbabwe: a toxicoepidemiological study.

Authors:  D E Ball; D Tagwireyi; C F B Nhachi
Journal:  J Appl Toxicol       Date:  2002 Sep-Oct       Impact factor: 3.446

5.  Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate.

Authors:  E W McChesney
Journal:  Am J Med       Date:  1983-07-18       Impact factor: 4.965

6.  Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort.

Authors:  Josiane Bourré-Tessier; Murray B Urowitz; Ann E Clarke; Sasha Bernatsky; Mori J Krantz; Thao Huynh; Lawrence Joseph; Patrick Belisle; Sang-Cheol Bae; John G Hanly; Daniel J Wallace; Caroline Gordon; David Isenberg; Anisur Rahman; Dafna D Gladman; Paul R Fortin; Joan T Merrill; Juanita Romero-Diaz; Jorge Sanchez-Guerrero; Barri Fessler; Graciela S Alarcón; Kristján Steinsson; Ian N Bruce; Ellen Ginzler; Mary Anne Dooley; Ola Nived; Gunnar Sturfelt; Kenneth Kalunian; Manuel Ramos-Casals; Michelle Petri; Asad Zoma; Christian A Pineau
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-01       Impact factor: 4.794

7.  RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.

Authors:  Mandeep R Mehra; Sapan S Desai; Frank Ruschitzka; Amit N Patel
Journal:  Lancet       Date:  2020-05-22       Impact factor: 79.321

8.  Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.

Authors:  Yishay Szekely; Yael Lichter; Bander Abu Shrkihe; Hila Bruck; Howard S Oster; Sami Viskin
Journal:  Heart Rhythm       Date:  2020-05-05       Impact factor: 6.343

Review 9.  Effects of chloroquine on viral infections: an old drug against today's diseases?

Authors:  Andrea Savarino; Johan R Boelaert; Antonio Cassone; Giancarlo Majori; Roberto Cauda
Journal:  Lancet Infect Dis       Date:  2003-11       Impact factor: 25.071

10.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

Authors:  Manli Wang; Ruiyuan Cao; Leike Zhang; Xinglou Yang; Jia Liu; Mingyue Xu; Zhengli Shi; Zhihong Hu; Wu Zhong; Gengfu Xiao
Journal:  Cell Res       Date:  2020-02-04       Impact factor: 25.617

View more
  8 in total

1.  A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam.

Authors:  Jeremy N Day; Nguyen Van Vinh Chau; Evelyne Kestelyn; Nguyen Thi Phuong Dung; Yen Lam Minh; Le Manh Hung; Nguyen Minh Quan; Nguyen Thanh Dung; Ngo Ngoc Quang Minh; Tran Chanh Xuan; Nguyen Thanh Phong; Van Ninh Thi Thanh; Joseph Donovan; Tran Nguyen Hoang Tu; Le Thanh Hoang Nhat; Nguyen Thanh Truong; Dinh Nguyen Huy Man; Huynh Phuong Thao; Nghiêm My Ngoc; Vo Thanh Lam; Huynh Hong Phat; Phan Minh Phuong; Ronald B Geskus; Vo Thi Nhi Ha; Nguyen Ngo Quang; Hien Tran Tinh; Le Van Tan; Guy E Thwaites
Journal:  Wellcome Open Res       Date:  2020-06-12

Review 2.  SARS-CoV-2 cell entry and targeted antiviral development.

Authors:  Zinuo Chen; Ruikun Du; Jazmin M Galvan Achi; Lijun Rong; Qinghua Cui
Journal:  Acta Pharm Sin B       Date:  2021-05-13       Impact factor: 11.413

3.  Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Marion Mafham; Louise Linsell; Jennifer L Bell; Natalie Staplin; Jonathan R Emberson; Martin Wiselka; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Tony Whitehouse; Timothy Felton; John Williams; Jakki Faccenda; Jonathan Underwood; J Kenneth Baillie; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Wei Shen Lim; Alan Montgomery; Kathryn Rowan; Joel Tarning; James A Watson; Nicholas J White; Edmund Juszczak; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-10-08       Impact factor: 91.245

4.  Randomized Controlled Trial of the Electrocardiographic Effects of Four Antimalarials for Pregnant Women with Uncomplicated Malaria on the Thailand-Myanmar Border.

Authors:  Makoto Saito; Widi Yotyingaphiram; Zillah Cargill; Mary Ellen Gilder; Aung Myat Min; Aung Pyae Phyo; Thi Dar San; Hilda Poe; Cindy Chu; Nicholas J White; François Nosten; Rose McGready
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

5.  Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform.

Authors:  Christopher T Rentsch; Nicholas J DeVito; Brian MacKenna; Caroline E Morton; Krishnan Bhaskaran; Jeremy P Brown; Anna Schultze; William J Hulme; Richard Croker; Alex J Walker; Elizabeth J Williamson; Chris Bates; Seb Bacon; Amir Mehrkar; Helen J Curtis; David Evans; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel Y S Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen J W Evans; Laurie Tomlinson; Ben Goldacre
Journal:  Lancet Rheumatol       Date:  2020-11-05

6.  Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19.

Authors:  Xiuge Gao; Xian Jing; Junqi Wang; Yuling Zheng; Yawei Qiu; Hui Ji; Lin Peng; Shanxiang Jiang; Wenda Wu; Dawei Guo
Journal:  Chem Biol Interact       Date:  2022-04-22       Impact factor: 5.168

7.  Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.

Authors:  Palang Chotsiri; Joel Tarning; Richard M Hoglund; James A Watson; Nicholas J White
Journal:  Clin Pharmacol Ther       Date:  2022-06-22       Impact factor: 6.903

8.  Does hydroxychloroquine still have any role in the COVID-19 pandemic?

Authors:  William Hk Schilling; Nicholas J White
Journal:  Expert Opin Pharmacother       Date:  2021-03-16       Impact factor: 3.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.